<?xml version="1.0" encoding="UTF-8"?>
<p>On another note, SwissADME online web tool revealed that all the examined pyridazines were found to comply with all druglikeness rules defined by the pioneer pharmaceutical companies; Veber’s (GSK)
 <xref rid="CIT0040" ref-type="bibr">
  <sup>40</sup>
 </xref>, Lipinski’s (Pfizer)
 <xref rid="CIT0041" ref-type="bibr">
  <sup>41</sup>
 </xref>, Egan’s (Pharmacia)
 <xref rid="CIT0042" ref-type="bibr">
  <sup>42</sup>
 </xref>, Ghose’s (Amgen)
 <xref rid="CIT0043" ref-type="bibr">
  <sup>43</sup>
 </xref> and Muegge’s (Bayer)
 <xref rid="CIT0044" ref-type="bibr">
  <sup>44</sup>
 </xref> filters, with an exception for compound 
 <bold>11e</bold> (towards Egan, Ghose and Muegge rules) and compound 
 <bold>11h</bold> (towards Egan and Ghose rules) (
 <xref rid="t0007" ref-type="table">Table 7</xref>). Interestingly enough, from the medicinal chemistry point of view the four examined pyridazines have neither PAINS (Pan Assay Interference Structures)
 <xref rid="CIT0045" ref-type="bibr">
  <sup>45</sup>
 </xref> alerts nor Brenks (Structural) alerts
 <xref rid="CIT0046" ref-type="bibr">
  <sup>46</sup>
 </xref>, which emphasises that their chemical structures lack any interfering framework that could result in an artefact in any protein assay implying that the obtained results from the 
 <italic>in vitro</italic> biological assays are to be robust.
</p>
